Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals executive Raymond J. Furey, EVP, GC, CCO & Corp Sec, reported a disposition of common stock. On February 2, 2026, he disposed of 3,968 shares of Rigel common stock at $36.01 per share, reported with transaction code F.
After this transaction, Furey directly beneficially owned 35,862 common shares, which the disclosure notes includes 1,000 shares acquired under Rigel’s stock purchase plan.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported multiple insider stock transactions. On January 26, 2026, he exercised employee stock options in two 40,000-share lots at $27.40 per share and reported related dispositions of 35,211 and 35,424 common shares at $37 per share.
On February 2, 2026, he reported an additional disposition of 14,110 common shares at $36.01 per share. After these transactions, he directly beneficially owned 235,709 Rigel common shares, including 1,000 shares acquired under the company’s stock purchase plan. All share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
Rigel Pharmaceuticals director receives new stock option grant. Director Michael Patrick Miller was awarded a stock option for 12,000 shares of Rigel common stock on February 1, 2026, with an exercise price of $34.86 per share. The option vests in equal monthly installments from February 1, 2026 until the annual meeting at which he is first scheduled to be considered for election by stockholders, conditioned on his continued service on the board.
Rigel Pharmaceuticals director Michael Patrick Miller reported his initial ownership of company securities. He directly holds 187 shares of common stock and a stock option for 625 shares at an exercise price of $16.05 per share, expiring on October 3, 2034.
Of this option, 375 shares are already vested. The remaining 250 option shares will vest in substantially equal installments on February 28, March 29, April 29, and May 29, 2026, giving a clear schedule for when he gains full option rights.
Rigel Pharmaceuticals, Inc. appointed Michael P. Miller to its board of directors effective February 1, 2026. He will serve in the director class whose term ends at the 2027 annual stockholders’ meeting and will also join the company’s Compensation Committee.
As a non-employee director, Mr. Miller will receive a yearly cash retainer of $50,000, plus an additional annual $10,000 retainer for Compensation Committee service, both pro-rated for partial service periods. He received an initial stock option grant to purchase 12,000 shares of common stock under Rigel’s 2018 Equity Incentive Plan.
After each annual stockholders’ meeting, he will automatically receive an annual option to purchase 3,000 shares of common stock and 2,500 restricted stock units, pro-rated for any year of partial service, so long as he continues to serve as a non-employee director. The company entered into its standard indemnification agreement with him and states that he is independent, has no disclosable related-party transactions, and no family relationships with the company’s directors or executive officers.
Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025. These estimates are based on currently available information and do not include all details needed for a complete picture of the company’s financial condition or operating results for that period.
The company also disclosed that it issued a press release titled “Rigel Provides Business Update and 2026 Outlook,” which is included as Exhibit 99.1. That release contains a broader business update and the company’s outlook for 2026, and is incorporated by reference into this report.
Rigel Pharmaceuticals' EVP & Chief Financial Officer reported option exercises and updated holdings. On 12/22/2025, the officer exercised three employee stock options (code M), acquiring 1,987 shares at $20, 2,846 shares at $24.2, and 1,667 shares at $18.7 per share.
Following these transactions, the officer beneficially owned 64,235 shares of Rigel common stock, which includes 500 shares acquired under the company’s stock purchase plan. The filing also shows remaining employee stock options covering 14,262, 17,153, and 10,832 shares, with expiration dates ranging from 01/23/2029 to 01/26/2033. All share numbers reflect a one-for-ten reverse stock split effective June 27, 2024, and the options vest in equal monthly installments over four years from their respective vesting commencement dates.
Rigel Pharmaceuticals furnished a press release announcing its financial results for the third quarter ended September 30, 2025 and providing a business update. The press release was included as Exhibit 99.1.
The company specified that this information is furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other SEC filings.
Rigel Pharmaceuticals reported strong Q3 2025 results. Total revenue was $69,462 (thousands), driven by net product sales of $64,067 (thousands) and collaboration revenue of $5,395 (thousands). Operating income reached $28,420 (thousands), and net income was $27,900 (thousands), or diluted EPS of $1.46. Gross product sales were $85,624 (thousands) offset by $21,557 (thousands) in discounts and allowances.
For the nine months ended September 30, 2025, revenue was $224,480 (thousands) and net income was $98,959 (thousands), aided by a $39,981 (thousands) release of cost share liability recognized in Q2. Cash, cash equivalents and short‑term investments were $137,200 (thousands) as of September 30, 2025. Customer concentration remained high, with McKesson accounting for 48% of Q3 net product sales. Shares outstanding were 18,151,344 as of October 30, 2025.
Rigel Pharmaceuticals, Inc. received joint Schedule 13G/A filings from Morgan Stanley and Morgan Stanley Capital Services LLC reporting passive ownership in the company's common stock. The combined report shows 116,406 shares beneficially owned by Morgan Stanley with 0.7% of the class and 71,545 shares by Morgan Stanley Capital Services LLC representing 0.4%. Both filers state they have 0 shares of sole voting or dispositive power and report shared voting/dispositive powers for the listed amounts. The filings note that, as of the filing date, each filer has ceased to be the beneficial owner of more than 5% of the class and include standard certifications on ordinary-course holdings.